Reprint
Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers
Edited by
January 2022
298 pages
- ISBN978-3-0365-2687-4 (Hardback)
- ISBN978-3-0365-2686-7 (PDF)
This book is a reprint of the Special Issue Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody–Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
monoclonal antibody; NSCLC; immunotherapy; ELISA; pharmacokinetics; pharmacogenetics; anti-PD-1 monoclonal antibodies; anti-acetylcholine receptor (AChR) antibody; B cell; immune checkpoint blockade; immune-related adverse events (irAEs); myasthenia gravis (MG); non-small-cell lung cancer (NSCLC); nivolumab; programmed cell death ligand 1 (PD-L1); T cell; tetraspanins; cancer; Tspan8; immunotherapy; radioimmunotherapy; immune-checkpoint inhibitors; LDH; biomarkers; Ang-2; antiangiogenic therapy; in vivo imaging; radio- and chemotherapy; VEGF-A; cancer therapy; neovascularization; angiogenesis; tumor microenvironment; colorectal cancer; immunotherapy; antibody; NK cells; ADCC; CD133; prominin-1; gold nanoparticles; antibody-drug conjugates; cell penetrating peptide; HIV-1 TAT; active-targeting; targeted delivery; trastuzumab; MMAE; valine-citrulline; affibody; drug conjugates; hepatic uptake; DM1; dermatooncology; immune checkpoints; immunotherapy; monoclonal antibodies; passive immunotherapy; canine B-cell lymphoma; DLA-DR; HLA-DR; antibody-drug conjugate; ADC; methotrexate; immune checkpoints; monoclonal antibodies; immunotherapy; tumor immunity; combination therapy; multiple myeloma (MM); immunotherapy; monoclonal antibodies (mAbs); antibody products; B cell maturation antigens (BCMAs); bispecific T cell engagers (BiTEs®); checkpoint inhibitors 1; protein structure 2; pharmacokinetics 3; drug optimization 4; HER2-positive breast cancer; metastatic disease; neoadjuvant and adjuvant therapy; targeted therapy; immunotherapy; acute myeloid leukemia; antibody-drug conjugate; CD123; IL3RA; kinesin spindle protein inhibitor